Raloxifene modulates estrogen-mediated B cell autoreactivity in NZB/W F1 mice

Journal of Rheumatology

Volumn 37, Issue 8, 2010, Pages 1646-1657

  Zhang, Yu ^a   Saha, Subhrajit ^a   Rosenfeld, Gabriel ^a   Gonzalez, Juana ^a   Pepeljugoski, Kiril P ^a   Peeva, Elena ^a,b  

^a Department of Medicine ^*  (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

B cells; Estrogen; NZB W F1 mice; Raloxifene; Systemic lupus erythematosus

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD22 ANTIGEN; CD40 ANTIGEN; DOUBLE STRANDED DNA; DOUBLE STRANDED DNA ANTIBODY; ESTROGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G3; RALOXIFENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL MATURATION; CELL SELECTION; CELL SURVIVAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; FEMALE; GLOMERULUS; IMMUNOGLOBULIN DEPOSITION; KIDNEY INJURY; MOUSE; NEW ZEALAND BLACK MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, CD40; B-LYMPHOCYTE SUBSETS; CELLS, CULTURED; DNA; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; GLOMERULAR MESANGIUM; IMMUNOGLOBULIN G; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED NZB; OVARIECTOMY; RALOXIFENE; SPLEEN;

EID: 77955480480     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090911     Document Type: Article

References (73)

1. Zandman-Goddard G, Peeva E, Shoenfeld Y. Gender and autoimmunity. Autoimmun Rev 2007;6:366-72.
2. Petri M, Howard D, Repke J. Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience. Arthritis Rheum 1991;34:1538-45.
3. Lahita R, Bradlow H. Klinefelter's syndrome: hormone metabolism in hypogonadal males with systemic lupus erythematosus. J Rheumatol 1987;14:154-7.
4. Lahita RG, Bradlow HL, Kunkel HG, Fishman J. Increased 16 alpha-hydroxylation of estradiol in systemic lupus erythematosus. J Clin Endocrinol Metab 1981;53:174-8.
5. Sanchez-Guerrero J, Liang MH, Karlson EW, Hunter DJ, Colditz GA. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med 1995;122:430-3.
6. Meier C, Sturkenboom M, Cohen A, Jick H. Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus. J Rheumatol 1998;25:1515-9.
7. Arden N, Lloyd M, Spector T, Hughes G. Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE). Lupus 1994;3:11-3.
8. Kreidstein S, Urowitz M, Gladman D, Gough J. Hormone replacement therapy in systemic lupus erythematosus. J Rheumatol 1997;24:2149-52.
9. Mok C, Lau C, Ho C, Lee K, Mok M, Wong R. Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus. Scand J Rheumatol 1998;27:342-6.
10. Buyon J, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005;142:953-62.
11. Sturgess A, Evans D, Mackay I, Riglar A. Effects of the oestrogen antagonist tamoxifen on disease indices in systemic lupus erythematosus. J Clin Lab Immunol 1984;13:11-4.
12. Mok C, To C, Mak A, Ma K. Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study. Arthritis Rheum 2005;52:3997-4002.
13. Couse J, Korach K. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 1999;20:358-417.
14. McDonnell D, Norris J. Connections and regulation of the human estrogen receptor. Science 2002;296:1642-4.
15. Li J, McMurray R. Effects of estrogen receptor subtype-selective agonists on autoimmune disease in lupus-prone NZB/NZW F1 mouse model. Clin Immunol 2007;123:219-26.
16. Svenson J, EuDaly J, Ruiz P, Korach K, Gilkeson G. Impact of estrogen receptor deficiency on disease expression in the NZM2410 lupus prone mouse. Clin Immunol 2008;128:259-68.
17. Wijayaratne A, Nagel S, Paige L, Christensen D, Norris J, Fowlkes D, et al. Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 1999;140:5828-40.
18. Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 2000;18:3172-86.
19. Bagdade J, Wolter J, Subbaiah P, Ryan W. Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J Clin Endocrinol Metab 190;70:1132-5.
20. Hadji P, Ziller M, Kieback D, Menschik T, Kalder M, Kuck J, et al. The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial. Breast 2009;18:159-64.
21. Francucci C, Romagni P, Boscaro M. Raloxifene: bone and cardiovascular effects. J Endocrinol Invest 2005;28:85-9.
22. Morrow M, Jordan V. Tamoxifen to prevent breast cancer. Adv Surg 2000;34:287-99.
23. Cummings S, Eckert S, Krueger K, Grady D, Powles T, Cauley J, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97.
24. Cohen F, Watts S, Shah A, Akers R, Plouffe L Jr. Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60. Obstet Gynecol 2000;95:104-10.
25. Onoe Y, Miyaura C, Ito M, Ohta H, Nozawa S, Suda T. Comparative effects of estrogen and raloxifene on B lymphopoiesis and bone loss induced by sex steroid deficiency in mice. J Bone Miner Res 2000;15:541-9.
26. Wu W, Lin B, Su Y, Suen J, Chiang B. Tamoxifen decreases renal inflammation and alleviates disease severity in autoimmune NZB/W F1 mice. Scand J Immunol 2000;52:393-400.
27. Sthoeger Z, Zinger H, Mozes E. Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies. Ann Rheum Dis 2003;62:341-6.
28. Peeva E, Venkatesh J, Diamond B. Tamoxifen blocks estrogen-induced B cell maturation but not survival. J Immunol 2005;175:1415-23.
29. Kim S, Suzuki N, Laxmi Y, Shibutani S. Genotoxic mechanism of tamoxifen in developing endometrial cancer. Drug Metab Rev 2004;36:199-218.
30. Erlandsson M, Jonsson CA, Islander U, Ohlsson C, Carlsten H. Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice. J Endocrinol 2002;175:319-27.
31. Smithson G, Couse J, Lubahn D, Korach K, Kincade P. The role of estrogen receptors and androgen receptors in sex steroid regulation of B lymphopoiesis. J Immunol 1998;161:27-34.
32. Bynoe M, Grimaldi C, Diamond B. Estrogen up-regulates Bcl-2 and blocks tolerance induction of naive B cells. Proc Natl Acad Sci USA 2000;97:2703-8.
33. Peeva E, Grimaldi C, Spatz L, Diamond B. Bromocriptine restores tolerance in estrogen-treated mice. J Clin Invest 2000;106:1373-9.
34. Devey ME, Lee SR, Le Page S, Feldman R, Isenberg DA. Serial studies of the IgG subclass and functional affinity of DNA antibodies in systemic lupus erythematosus. J Autoimmun 1988;1:483-94.
35. Zeng D, Liu Y, Sidobre S, Kronenberg M, Strober S. Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J Clin Invest 2003;112:1211-22.
36. Takahashi S, Nose M, Sasaki J, Yamamoto T, Kyogoku M. IgG3 production in MRL/lpr mice is responsible for development of lupus nephritis. J Immunol 1991;147:515-9.
37. Carsetti R, Köhler G, Lamers M. Transitional B cells are the target of negative selection in the B cell compartment. J Exp Med 1995;181:2129-40.
38. Ramanujam M, Wang X, Huang W, Schiffer L, Grimaldi C, Akkerman A, et al. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 2004;173:3524-34.
39. Grimaldi C, Michael D, Diamond B. Cutting edge: expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. J Immunol 2001;167:1886-90.
40. Srivastava B, Lindsley RC, Nikbakht N, Allman D. Models for peripheral B cell development and homeostasis. Semin Immunol 2005;17:175-82.
41. Martin F, Kearney J. B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a "natural immune memory". Immunol Rev 2000;175:70-9.
42. Chavez-Rueda K, Legorreta-Haquet V, Cervera-Castillo H, Sánchez L, Jara L, Zenteno E, et al. Effect of prolactin on lymphocyte activation from systemic lupus erythematosus patients. Ann N Y Acad Sci 2007;1108:157-65.
43. Nitschke L, Carsetti R, Ocker B, Kohler G, Lamers MC. CD22 is a negative regulator of B-cell receptor signaling. Curr Biol 1997;7:133-43.
44. O'Keefe T, Williams G, Batista F, Neuberger M. Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 1999;189:1307-13.
45. Yellin M, Thienel U. T cells in the pathogenesis of systemic lupus erythematosus: potential roles of CD154-CD40 interactions and costimulatory molecules. Curr Rheumatol Rep 2000;2:24-31.
46. Datta S. Production of pathogenic antibodies: cognate interactions between autoimmune T and B cells. Lupus 1998;7:591-6.
47. Lambert P, Dixon F. Pathogenesis of the glomerulonephritis of NZB/W mice. J Exp Med 1968;127:507-22.
48. Garcia-Perez M, Del Val R, Noguera I, Hermenegildo C, Pineda B, Martinez-Romero A, et al. Estrogen receptor agonists and immune system in ovariectomized mice. Int J Immunopathol Pharmacol 2006;19:807-19.
49. Medina KL, Strasser A, Kincade PW. Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors. Blood 2000;95:2059-67.
50. Nilsson N, Carlsten H. Estrogen induces suppression of natural killer cell cytotoxicity and augmentation of polyclonal B cell activation. Cell Immunol 1994;158:131-9.
51. Carlsten H, Tarkowski A. Histocompatibility complex gene products and exposure to oestrogen: two independent disease accelerating factors in murine lupus. Scand J Immunol 1993;38:341-7.
52. Ahmed S, Verthelyi D. Antibodies to cardiolipin in normal C57BL/6J mice: induction by estrogen but not dihydrotestosterone. J Autoimmun 1993;6:265-79.
53. Grimaldi CM, Jeganathan V, Diamond B. Hormonal regulation of B cell development: 17 beta-estradiol impairs negative selection of high-affinity DNA-reactive B cells at more than one developmental checkpoint. J Immunol 2006;176:2703-10.
54. Cano A, Hermenegildo C. The endometrial effects of SERMs. Hum Reprod Update 2000;6:244-54.
55. Cline JM, Soderqvist G, Register TC, Williams JK, Adams MR, Von Schoultz B. Assessment of hormonally active agents in the reproductive tract of female nonhuman primates. Toxicol Pathol 2001;29:84-90.
56. Greaves P, White IN. Experimental adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006;20:503-10.
57. Reginster JY, Devogelaer JP. Raloxifene reduces fractures in postmenopausal women with osteoporosis. Clin Orthop Relat Res 2006;443:48-54.
58. Turner CH, Sato M, Bryant HU. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 1994;135:2001-5.
59. Boss SM, Huster WJ, Neild JA, Glant MD, Eisenhut CC, Draper MW. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997;177:1458-64.
60. Black L, Keder R, Bourne T, Powles T, Collins W, Ashley S, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 1994;343:1318-21.
61. Nalbandian G, Paharkova-Vatchkova V, Mao A, Nale S, Kovats S. The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation. J Immunol 2005;175:2666-75.
62. Liu H, Buenafe AC, Matejuk A, Ito A, Zamora A, Dwyer J, et al. Estrogen inhibition of EAE involves effects on dendritic cell function. J Neurosci Res 2002;70:238-48.
63. Colletta A, Wakefield L, Howell F, van Roozendaal K, Danielpour D, Ebbs S, et al. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 1990;62:405-9.
64. Dayan M, Zinger H, Kalush F, Mor G, Amir-Zaltzman Y, Kohen F, et al. The beneficial effects of treatment with tamoxifen and anti-oestradiol antibody on experimental systemic lupus erythematosus are associated with cytokine modulations. Immunology 1997;90:101-8.
65. Wu W, Suen J, Lin B, Chiang B. Tamoxifen alleviates disease severity and decreases double negative T cells in autoimmune MRL-lpr/lpr mice. Immunology 2000;100:110-8.
66. Dixon A, Wells C, Singh S, Babayan R, Maric C. Renoprotective effects of a selective estrogen receptor modulator, raloxifene, in an animal model of diabetic nephropathy. Am J Nephrol 2007;27:120-8.
67. O'Keefe T, Williams G, Davies S, Neuberger M. Hyperresponsive B cells in CD22-deficient mice. Science 1996;274:798-801.
68. Early G, Zhao W, Burns C. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol 1996;157:3159-64.
69. Huang W, Sinha J, Newman J, Reddy B, Budhai L, Furie R, et al. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum 2002;46:1554-62.
70. Kuiper G, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors a and b. Endocrinology 1997;138:863-70.
71. Feng F, Nyland J, Banyai M, Tatum A, Silverstone A, Gavalchin J. The induction of the lupus phenotype by estrogen is via an estrogen receptor-alpha-dependent pathway. Clin Immunol 2010;134:226-36. Epub 2009 Nov 17.
72. Paech K, Webb P, Kuiper G, Nilsson S, Gustafsson J, Kushner P, et al. Differential ligand activation of estrogen receptors ERα and ERß at AP1 sites. Science 1997;277:1508-10.
73. Matthews J, Gustafsson J. Estrogen signaling: a subtle balance between ER α and ER ß. Mol Interv 2003;3:281-92.